Frontlight ResearchEarly access
TerminatedNo phase
Blood Samples to Identify Biomarkers of Busulfan
Key facts
- Who runs it
- Fred Hutchinson Cancer Center
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 139 people enrolled
- Started
- Nov 2014
- Ended
- 7 Oct 2024
- Type of study
- Observational
- Record updated
- 3 March 2025
- Why it stopped
- Study terminated due to end of funding
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Scheduled to receive targeted intravenous busulfan (any dose, any number of doses, any dosing frequency) as part of their hematopoietic stem cell transplant conditioning
- Weight > 21kg
Who cannot take part
- Life expectancy severely limited by diseases other than malignancy
- Unable to read English
- Female patients who are pregnant or breastfeeding
Where in United States
- University of WashingtonSeattle, United States
About the trial
What the trial wants to find out
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance.
Read full original descriptionShow less
Specific Aim 2: To characterize IV BU metabolism by metabolomics.
Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics
- Record updated
- 3 March 2025